Microbiome restoration - FVT

Phase 1

Microbiome restoration - FVT is one of 2 therapeutic programs targeting Microbial Colonization. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Microbial ColonizationRecruiting

Microbial ColonizationPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Microbial Colonization

#DrugCompanyPhaseTrials

Microbiome Restoration - FMT

PProfessor Klaus Bønnelykke

Phase 1

1 2

Microbiome restoration - FVT

JJakob Stokholm

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Microbial Colonization

NCT06264219

Clinical

Trials by Indication[1]

Microbial Colonization1 trial

"Restoration of the Gut Microbiome After Cesarean Section (RestoreGut)" - A Double-blinded Randomized Placebo-controlled Trial

Recruiting·PProfessor Klaus Bønnelykke·Phase 1·NCT06264219·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microbiome restoration - FVT. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Microbiome restoration - FVT. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jakob Stokholm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: JJakob Stokholm

Microbiome restoration - FVT

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Microbial Colonization1 trial

References

Drug Info

Quick Facts

Related News